Risco-Risco, CarlosHenriquez-Camacho, CésarHerrera-Rueda, MartaBarberán, JoséAndaluz-Ojeda, David2026-01-282026-01-282024-11Risco-Risco, C, Henriquez-Camacho, C, Herrera-Rueda, M, Barberán, J & Andaluz-Ojeda, D 2024, 'Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria : A Systematic Review and Meta-Analysis', Antibiotics, vol. 13, no. 11, 1048. https://doi.org/10.3390/antibiotics131110482079-6382PubMedCentral: PMC11591197https://hdl.handle.net/10641/7659Publisher Copyright: © 2024 by the authors.1792479enghttp://creativecommons.org/licenses/by-nc-nd/4.0/Acinetobacter baumanniiGram-negative bacteriaICUMDRcefiderocolcritically illsevere infectionsMicrobiologyBiochemistryGeneral Pharmacology, Toxicology and PharmaceuticsMicrobiology (medical)Infectious DiseasesPharmacology (medical)SDG 3 - Good Health and Well-beingJournal ArticleReviewYesyesreview articleopen access10.3390/antibiotics13111048https://www.scopus.com/pages/publications/85210403790https://www.scopus.com/pages/publications/85210403790#tab=citedBy